Linagliptin

Orukọ Kemikali:

8-[(3R) -3-aminoperidin-1-yl] -7- (ṣugbọn-2-yn-1-yl) -3- methyl-1-[(4-methylquinazolin-2-yl) methyl]-3 ,7-dihydro-1H-purine-2,6-dione

KỌỌDỌ SMILES:

O=C(N1CC2=NC(C)=C3C=CC=CC3=N2)N(C)C4=C(N(CC#CC)C(N5C[C@H](N)CCC5)=N4)C1 =O

Koodu InChi:

InChi=1S/C25H28N8O2/c1-4-5-13-32-21-22(29-24(32)31-12-8-9-17(26)14-31)30(3)25(35) 33 (23 (21) 34) 15-20-27-16 (2) 18-10-6-7-11-19 (18) 28-20 / h6-7,10-11,17H,8-9, 12-15,26H2,1-3H3/t17-/m1/s1

Bọtini InChi:

LTXREWYXXSTFRX-QGZVFWFLSA-N

Koko-ọrọ:

Linagliptin, BI-1356, BI 1356, BI1356, 668270-12-0

Solubility:Tiotuka ni DMSO

Ibi ipamọ:0 - 4°C fun igba kukuru (ọjọ si awọn ọsẹ), tabi -20°C fun igba pipẹ (osu).

Apejuwe:

Linagliptin, ti a tun mọ ni BI-1356, jẹ inhibitor DPP-4 ti o dagbasoke nipasẹ Boehringer Ingelheim fun itọju iru àtọgbẹ II. Linagliptin (ẹẹkan lojoojumọ) jẹ ifọwọsi nipasẹ US FDA ni ọjọ 2 Oṣu Karun ọdun 2011 fun itọju iru àtọgbẹ II. Boehringer Ingelheim ati Lilly n ta ọja rẹ.

Àfojúsùn: DPP-4